MAXIGEN BIOTECH
 | The topic of this article may not meet Wikitia's general notability guideline. |
Native name | 和康生物科技股份有限公司 |
|---|---|
| Public | |
| Traded as | 1783 |
| Industry | medical device |
| Founded | 3 December 1998 |
| Headquarters | No.88, Keji 1st Rd., Guishan Dist.,, Taoyuan City , |
Area served | Worldwide |
Key people |
|
| Products |
|
Number of employees |  120 (2023) |
| Website | mbi-bio.com |
Maxigen Biotech Inc. (MBI), founded in 1998 in Taiwan, specialises in biomedical products like medical equipment and consumables, with a focus on collagen and hyaluronic acid. Their offerings include intra-articular injections, synthetic bone grafts, regenerative matrices, dermal fillers, and ophthalmic viscoelastics.
In 2021, MBI became part of the TCI Group and received investment from Formosa Biomedical Technology Corp. MBI also serves various key stakeholders like TCI Bio and NuVasive Inc., and reported revenue exceeding USD20 million in 2022. While currently successful in 22 countries.
With a robust supply chain, R&D efforts, customer diligence, and strategic partnerships that contribute to its resilience, MBI envisions growth as an opportunity to solidify its global standing and emphasise agility. Its focus on innovation, customer-centricity, and financial stability also play a critical role in MBI’s success.
References
External links
This article "MAXIGEN BIOTECH" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.